Skip to main content
SpringerLink
Log in

Update zur ECHELON-1-Studie

Stellenwert von Brentuximab Vedotin bei fortgeschrittenem Hodgkin-Lymphom

  • Journal club
  • Published:
InFo Hämatologie + Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur:

  1. Engert A et al. J Clin Oncol. 2009;27(27):4548-54

  2. Hiller E. InFo Hämatologie + Onkologie. 2018;21(3):16-7

  3. Connors JM et al. N Engl J Med. 2018;378(4):331-44

  4. Straus DJ et al. Blood. 2020;135(10):735-42

  5. Zimmermann A et al. In: Manual Maligne Lymphome. 11. Auflage. München: Tumorzentrum München und Zuckschwerdt-Verlag; 2019. S. 75-99

Download references

Author information

Authors and Affiliations

  1. Hämato-onkologische Gemeinschafts-, Winthierstr. 7, 80639, München, Germany

    Erhard Hiller

Authors
  1. Erhard Hiller
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hiller, E. Stellenwert von Brentuximab Vedotin bei fortgeschrittenem Hodgkin-Lymphom. InFo Hämatol Onkol 23, 22–23 (2020). https://doi.org/10.1007/s15004-020-8066-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-020-8066-8

Search

Navigation